Weiguo Ye - 11 Jun 2026 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Reporting relationship: Chief Operating Officer
Issuer ticker: GYRE
Reported as of: 11 Jun 2026
Net transaction value: -$17,276
SEC form: 4
Accepted by SEC: 15 Jun 2026, 16:01:12 UTC
Prior SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Weiguo Ye

Key filing fact

Weiguo Ye filed Form 4 for GYRE THERAPEUTICS, INC. (GYRE) on 15 Jun 2026.

Key facts

This page summarizes Weiguo Ye's Form 4 filing for GYRE THERAPEUTICS, INC. (GYRE).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 16:01.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: -$17,276.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001985496 Primary reporting owner

Ye Weiguo

Relationship: Chief Operating Officer
Address: C/O GYRE THERAPEUTICS, INC., 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO
Signature: /s/ Weiguo Ye
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GYRE transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,800
Change %: +0.4%
Price: $0.7500^*
Shares after: 702,800
Date: 11 Jun 2026
Ownership: Direct

GYRE transaction

Common Stock

Sale

Transaction value: $17,276
Shares: -2,800
Change %: -0.4%
Price: $6.17
Shares after: 700,000
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GYRE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -2,800
Change %: -0.33%
Price: $0.000000^*
Shares after: 838,701
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,800
Exercise price: $0.7500
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.18. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F2

These options are vested in full.